Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

第3相 実施中（募集終了） NCT02003222

概要

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.

Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy

Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years · months

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituxim — National Cancer Institute (NCI)
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual — National Cancer Institute (NCI)
• Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute — Wake Forest University Health Sciences
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Ri — National Cancer Institute (NCI)

すべての治験